Suven Life Sciences Limited has informed the Exchange regarding a press release dated February 06, 2024, titled "Suven Life Sciences Announces Randomization of First Patient in Phase-2 POC Clinical Trial of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder study in USA".